touchMEETING HIGHLIGHTS

Epilepsy FOCUS: Shared experience of cannabidiol

Watch Time: 170 mins

Faculty Presenters: Elizabeth Thiele, Selim Benbadis, Bernhard Steinhoff, Andreas Schulze-Bonhage, Ulrich Brandl, Angela Kaindl, Sameer Zuberi

This content is available for free to registered users, and is intended for HCPs only

to access this content

This activity has been sponsored by GW Pharmaceuticals, Plc. GW Pharmaceuticals, Plc. developed the Epilepsy FOCUS initiative, provided financial support for this activity, and has had input into the selection of the faculty and the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchNEUROLOGY.

Paediatric Neurology, Epilepsy View Time: 170 mins

touchMEETING HIGHLIGHTS Epilepsy FOCUS: Shared experience of cannabidiol

In the following two webinars, seven leading experts discuss case studies of patients treated with GW CBD, reviewing patient profiles, optimal dosing and titration, management of adverse events and polytherapy, and initiating GW CBD in patients previously on non-regulatory approved cannabis-based products. The topics highlighted in the webinars can easily be accessed from the panel on the left side of the page.

This content is available for free to registered users, and is intended for HCPs only.

  • Part 1: Webinars
Next Chapter
Webinar 2: Initiating patients with GW CBD
Watch Time: 04:59
Webinar 2: Managing adverse events and determining the optimal dose of GW CBD
Watch Time: 25:49
Webinar 2: Initiating GW CBD in patients who have previously received a non-regulatory approved cannabis-based product
Watch Time: 56:30
Webinar 2: Panel discussion and audience Q & A
Watch Time: 01:07:21
Webinar 1: GW CBD patient profile
Watch Time: 01:22:52
Webinar 1: Starting and maintaining patients on GW CBD and managing adverse events
Watch Time: 01:37:37
Webinar 1: GW CBD in patients who have tried or are currently receiving non-regulatory approved cannabis-based products
Watch Time: 02:15:12
 
Leave Feedback
Overview

Two webinars with seven leading experts discussing case studies of patients treated with cannabidiol.

About Faculty

Prof. Dr Elizabeth Thiele
Massachusetts General Hospital, Boston, USA

Prof. Dr Selim Benbadis
University of South Florida, Tampa, USA

Prof. Dr Bernhard Steinhoff
Kork Epilepsy Center and University of Freiburg, Freiburg in Breisgau, Germany

Prof. Dr Andreas Schulze-Bonhage
University Hospital Freiburg, Freiburg im Breisgau, Germany

Prof. Dr Ulrich Brandl
University Hospital Jena, Jena, Germany

Prof. Dr Angela Kaindl
Charité – Universitätsmedizin Berlin, Berlin, Germany

Prof. Dr Sameer Zuberi
Royal Hospital for Children, Glasgow, UK

Disclosures:

Prof. Dr Elizabeth Thiele: Consultant for GW Pharmaceuticals, Zogenix, Biocodex, Aquestive, West Therapeutics, RegenexBio. Research grants from GW Pharmaceuticals, Zogenix.

Prof. Dr Selim Benbadis: Consultant for Brain Sentinel, Cavion, Ceribell, Eisai, Greenwich, LivaNova, NeuroPace, SK Biopharmaceuticals, Sunovion. Speakers’ bureau for Eisai, Greenwich, LivaNova, Sunovion. National Medical Director for RSC Diagnostic Services (EEG). Florida Medical Director of Stratus/Alliance (EEG). Member of Epilepsy Study Consortium. Grant support from Cavion, LivaNova, Greenwich, SK Biopharmaceuticals, Sunovion, Takeda, Xenon. Royalties as an author or editor for eMedicine-Medscape-WebMD, UpToDate. Editorial board for Epilepsy.com (Epilepsy Foundation) controversy section, eMedicine-Medscape-WebMD, Epileptic Disorders, Epilepsy and Behaviour, Expert Review of Neurotherapeutics.

Prof. Dr Bernhard Steinhoff: Speaker honoraria from Al-Jazeera, Desitin, Eisai, GW Pharmaceuticals, Hikma, Novartis, Sandoz, UCB. Advisory boards or consultancy agreements from Arvelle, Bial, B. Braun, Desitin, Eisai, GW Pharmaceuticals, UCB.

Prof. Dr Andreas Schulze-Bonhage: Research support from Bial, BMBF, DFG, EU, HBP, NIH. Honoraria for lectures or advice from Arvelle, Bial, Eisai, GW Pharmaceuticals, UCB.

Prof. Dr Ulrich Brandl: Honoraria for presentations, lectures, or advisory boards from Bial, Desitin, Eisai, GW Pharmaceuticals, UCB, Zogenix.

Prof. Dr Angela Kaindl: Speaker honoraria from GW Pharmaceuticals.

Prof. Dr Sameer Zuberi: Sameer Zuberi is Consultant Paediatric Neurologist at the Royal Hospital for Children and Honorary Professor of Paediatric Neurology in the University of Glasgow. He leads the Paediatric Neurosciences Research Group and is clinical lead of the Scottish National Genetic Epilepsy Service. His other roles include President of the European Paediatric Neurology Society, Editor-in-Chief of the European Journal of Paediatric Neurology, past Chair of the International League Against Epilepsy (ILAE) Commission on Classification & Terminology (2013-17) and ILAE Nosology & Definitions Task Force Member.

Downloads

View and download resources from this activity to support your learning or share with colleagues.

  • Part 2: Expert Interviews
Leave Feedback
Prof. Dr Elizabeth Thiele
Watch Time: 08:14
Massachusetts General Hospital, Boston, USA

Elizabeth Thiele provides an overview of the diverse patient profiles of individuals with epilepsy who may benefit from GW CBD treatment, and how to initiate and escalate dosing, and manage adverse events.

 
Please Select A Video:
Leave Feedback
Overview & Learning Objectives
Overview

Epidyolex® is indicated for use as adjunctive therapy of seizures associated with LGS or DS, in conjunction with clobazam, for patients 2 years of age and older.

Epidyolex® is indicated for use as adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older.

This session is organised and funded by GW Pharmaceuticals, Plc. and is intended for an HCP or prescriber audience only. The indication may differ in your country; please refer to local prescribing information.

Learning Objectives

After watching this touchMEETING HIGHLIGHTS, you should be able to:

  • Describe some of the diverse profiles of patients who may benefit from cannabidiol
  • Understand how to initiate GW CBD and reach optimal dosing
  • Discuss potential strategies to manage patients experiencing adverse events (AEs)
  • Understand how to manage patients with previous or current experience of non-regulatory approved cannabis-based products
Adverse Events
Adverse Events

Adverse events should be reported according to local regulations. For the UK, reporting forms and information can be found on the MHRA yellow card site as yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to GW pharma on medinfo@gwpharm.com .

References
References

MHRA. Epidyolex Summary of product characteristics available at: mhraproducts10781.

Feedback Close
Feedback

Please provide feedback for this touchMEETING HIGHLIGHTS on the following
(scale of 1-5 where 1=strongly disagree and 5=strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72